Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01390844
First received: July 7, 2011
Last updated: August 2, 2016
Last verified: August 2016

July 7, 2011
August 2, 2016
October 2011
June 2015   (final data collection date for primary outcome measure)
  • Percentage of Participants in Korea and Taiwan With Sustained Virologic Response (SVR) at Follow-Up Week 24 - Full Analysis Set (FAS) Population [ Time Frame: Follow-up Week 24 ] [ Designated as safety issue: No ]
    SVR is defined as undetectable plasma HCV-RNA at Follow-up Week (FW) 24. If FW24 is missing and other HCV-RNA values after FW24 are available, the last available value would be used for FW24. The last observation carried forward (LOCF) method was used to impute missing values; if a participant is missing at and after FW24 and has FW12 data, then FW12 data will be carried forward to FW24. Cross-over participants are considered as non-responders in SVR.
  • Percentage of Participants in India With SVR at Follow-Up Week 24 - FAS Population [ Time Frame: Follow-up Week 24 ] [ Designated as safety issue: No ]
    SVR is defined as undetectable plasma HCV-RNA at FW24. If FW24 is missing and other HCV-RNA values after FW24 are available, the last available value would be used for FW24. The LOCF method was used to impute missing values; if a participant is missing at and after FW24 and has FW12 data, then FW12 data will be carried forward to FW24. Cross-over participants are considered as non-responders in SVR.
Sustained virologic response, defined as undetectable plasma hepatitis C virus ribonucleic acid (HCV-RNA) at Follow-up Week 24 in participants who received at least one dose of any trial medication (i.e. PEG, RBV, BOC, or placebo) [ Time Frame: Follow-up Week 24 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01390844 on ClinicalTrials.gov Archive Site
  • Percentage of Participants in Korea and Taiwan With SVR at Follow-Up Week 24 - Modified Intent-to-Treat (mITT) Population [ Time Frame: Follow-up Week 24 ] [ Designated as safety issue: No ]
    SVR is defined as undetectable plasma HCV-RNA at FW24. If FW24 is missing and other HCV-RNA values after FW24 are available, the last available value would be used for FW24. The LOCF method was used to impute missing values; if a participant is missing at and after FW24 and has FW12 data, then FW12 data will be carried forward to FW24. Cross-over participants are considered as non-responders in SVR.
  • Percentage of Participants in India With SVR at Follow-Up Week 24 - mITT Population [ Time Frame: Follow-up Week 24 ] [ Designated as safety issue: No ]
    SVR is defined as undetectable plasma HCV-RNA at FW24. If FW24 is missing and other HCV-RNA values after FW24 are available, the last available value would be used for FW24. The LOCF method was used to impute missing values; if a participant is missing at and after FW24 and has FW12 data, then FW12 data will be carried forward to FW24. Cross-over participants are considered as non-responders in SVR.
  • Percentage of Participants in Korea and Taiwan Achieving Early Virologic Response (EVR) at Treatment Week 8 [ Time Frame: Treatment Week 8 ] [ Designated as safety issue: No ]
    Percentage of participants achieving early virologic response (undetectable HCV-RNA at Treatment Week 8)
  • Percentage of Participants in India Achieving EVR at Treatment Week 8 [ Time Frame: Treatment Week 8 ] [ Designated as safety issue: No ]
    Percentage of participants achieving early virologic response (undetectable HCV-RNA at Treatment Week 8)
  • Percentage of Participants With an Adverse Event (AE) of Anemia in Korea and Taiwan [ Time Frame: Up to 96 weeks ] [ Designated as safety issue: Yes ]
    Anemia is a condition in which the number of red blood cells or hemoglobin concentration is insufficient to meet the body's physiologic needs. This measure gives the percentage of participants who experienced an occurrence of modified World Health Organization (WHO) grade 1-4 anemia during the treatment period. A higher grade indicates a higher degree of anemia. This table summarizes the worst category observed within the period per participant per laboratory test (i.e., the lowest value for the hemotologic parameters).
  • Percentage of Participants With an AE of Anemia in India [ Time Frame: Up to 96 weeks ] [ Designated as safety issue: Yes ]
    Anemia is a condition in which the number of red blood cells (hemoglobin) is insufficient to meet the body's physiologic needs. This measure gives the percentage of participants who experienced an occurrence of modified WHO grade 1-4 anemia during the treatment period. A higher grade indicates a higher degree of anemia. This table summarizes the worst category observed within the period per participant per laboratory test (i.e., the lowest value for the hemotologic parameters).
  • Percentage of Participants With an AE of Neutropenia in Korea and Taiwan [ Time Frame: Up to 96 weeks ] [ Designated as safety issue: Yes ]
    Neutropenia is an abnormally low level of white blood cells (neutrophils). This measure gives the percentage of participants who experienced an occurrence of modified WHO grade 1-4 neutropenia during the treatment phase. A higher grade indicates a higher degree of neutropenia. This table summarizes the worst category observed within the period for each participant.
  • Percentage of Participants With an AE of Neutropenia in India [ Time Frame: Up to 96 weeks ] [ Designated as safety issue: Yes ]
    Neutropenia is an abnormally low level of white blood cells (neutrophils). This measure gives the percentage of participants who experienced an occurrence of modified WHO grade 1-4 neutropenia during the treatment phase. A higher grade indicates a higher degree of neutropenia. This table summarizes the worst category observed within the period for each participant.
  • Sustained virologic response, defined as undetectable plasma HCV-RNA at Follow-up Week 24 in participants who received at least one dose of experimental trial medication (i.e. placebo or BOC) [ Time Frame: Follow-up Week 24 ] [ Designated as safety issue: No ]
  • Number of participants achieving early virologic response (undetectable HCV-RNA at Treatment Week 8) [ Time Frame: Treatment Week 8 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)
Safety and Efficacy of Boceprevir in Combination With Peginterferon Plus Ribavirin for Treatment of Asia Pacific Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Pegylated Interferon Plus Ribavirin
This study will assess the efficacy of boceprevir (BOC) in combination with PegIntron (pegylated interferon alfa-2b) (PEG) and ribavirin (RBV) in response guided therapy compared to the efficacy of standard-of-care therapy alone in adult subjects with chronic hepatitis C (CHC) genotype 1 who failed prior treatment with pegylated interferon and RBV in the Asia Pacific population. The primary hypothesis is that the proportion of participants achieving sustained virologic response in the experimental therapy regimen (BOC/PEG+RBV) is superior to that in the control arm (Placebo/PEG+RBV), in the Full Analysis Set (FAS) population.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Hepatitis C, Chronic
  • Drug: Boceprevir (BOC)
    200 mg capsules, 800 mg three times daily by mouth
    Other Names:
    • SCH 503034
    • Victrelis
  • Drug: Placebo to boceprevir
    200 mg placebo capsules, 800 mg three times daily by mouth
  • Drug: Peginterferon alfa-2b (PEG)
    1.5 mcg/kg/week subcutaneously
    Other Names:
    • PegIntron
    • SCH 054031
    • Redipen
  • Drug: Ribavirin (RBV)
    200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily
    Other Names:
    • Rebetol
    • SCH 018908
  • Drug: Cross-Over Boceprevir Treatment
    At Treatment Week 14, participants in the Placebo group with detectable HCV-RNA at Treatment Week 12 have the option to add boceprevir 800 mg three times daily to the PEG + RBV regimen for up to 32 weeks.
    Other Names:
    • SCH 503034
    • Victrelis
  • Experimental: Boceprevir
    PEG + RBV for 4 weeks followed by BOC + PEG + RBV for 32 weeks. At the Treatment Week 36 visit, participants with undetectable HCV-RNA at Treatment Weeks 8 and 12 will proceed to 36 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 8 and undetectable HCV-RNA at Treatment Week 12 will continue on BOC + PEG + RBV until Treatment Week 36, receive placebo + PEG + RBV until Treatment Week 48, and then proceed to 24 weeks of post-treatment follow-up. Participants with any HCV-RNA result at Treatment Week 8 and detectable HCV-RNA at Treatment Week 12 will discontinue treatment and proceed to 24 weeks of post-treatment follow-up.
    Interventions:
    • Drug: Boceprevir (BOC)
    • Drug: Placebo to boceprevir
    • Drug: Peginterferon alfa-2b (PEG)
    • Drug: Ribavirin (RBV)
  • Active Comparator: Control
    PEG + RBV for 4 weeks followed by BOC placebo + PEG + RBV for 44 weeks. Participants with undetectable HCV-RNA at Treatment Week 12 and at subsequent assays will continue on placebo + PEG + RBV through Treatment Week 48 and proceed to 24 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 12 may roll over to Cross-Over BOC treatment beginning with Treatment Week 14.
    Interventions:
    • Drug: Placebo to boceprevir
    • Drug: Peginterferon alfa-2b (PEG)
    • Drug: Ribavirin (RBV)
    • Drug: Cross-Over Boceprevir Treatment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
282
June 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Previously documented CHC genotype 1 infection. Other or mixed genotypes are not eligible.
  • Liver biopsy with histology consistent with CHC and no other etiology.
  • Participants with cirrhosis must have an ultrasound/imaging study within 6 months of screening (or between screening and Day 1) with no findings suspicious for hepatocellular carcinoma
  • Failed previous treatment (of at least 12 weeks) with pegylated interferon (alfa-2a or alfa-2b) plus RBV
  • Weight between 40 kg and 125 kg, inclusive
  • Of 'local' ancestral descent
  • Sexually active males and females of child-bearing potential must agree to use a medically accepted method of contraception

Exclusion Criteria:

  • Co-infected with the human immunodeficiency virus (HIV) or hepatitis B virus.
  • Required discontinuation of previous interferon or RBV regimen for an adverse event considered to be possibly or probably related to RBV and/or interferon.
  • Treatment with RBV within 90 days and any interferon-alpha within 1 month prior to screening.
  • Treatment for hepatitis C with any investigational medication or prior treatment with herbal remedies with known hepatotoxicity.
  • Treatment with any investigational drug or participation in any interventional clinical trial within 30 days of the screening visit.
  • Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy.
  • Diabetes and/or hypertension with clinically significant ocular examination findings.
  • Any condition the could interfere with participation in and completion of the trial.
  • Evidence of active or suspected malignancy, or history of malignancy within the last 5 years (except adequately treatment carcinoma in situ and basal cell carcinoma of the skin).
  • Pregnant or breast-feeding.
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
India,   Korea, Republic of,   Taiwan,   United States
 
NCT01390844
P07063, 2007-005151-42, 3034-033, CTRI/2012/04/002540
No
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Director Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP